

Anish Bhatnagar, MD | Chairman of the Board and Chief Executive Officer, Soleno Therapeutics

Dr. Bhatnagar, a physician by training, has been our Chief Executive Officer since the creation of Soleno in 2017. With nearly three decades in the biopharmaceutical and medical device industries, Dr. Bhatnagar's experience spans development of biologics, drugs, drug-device combinations and diagnostic as well as therapeutic medical devices. At Soleno, Dr. Bhatnagar leads the team responsible for developing and commercializing VYKAT XR, the first FDA-approved therapy for hyperphagia in Prader-Willi syndrome. His passion for delivering meaningful solutions for those impacted by rare diseases has been recognized with TIME Magazine naming him one of the 100 Most Influential People in Health for 2025, and his invited testimony to the United States Senate's Special Committee on Aging where he testified on "Unlocking Hope: Access to Therapies for People with Rare, Progressive and Serious Diseases."

Dr. Bhatnagar has also been involved in the development of various approved products, such as Bexxar (radioimmunotherapeutic for Non-Hodgkins lymphoma), Probuphine (for opioid addiction), Serenz (device for nasal allergies) and CoSense (diagnostic for neonatal hemolysis). Prior to Soleno, Dr. Bhatnagar served as Chief Executive Officer of Capnia, Inc. from February 2014 until March 2017 and held positions of increasing responsibility at Capnia from 2006. Prior to that he was at Titan Pharmaceuticals, Inc. from 2000 to 2006 and Coulter Pharmaceuticals, Inc. from 1998 to 2000.

Dr. Bhatnagar currently serves on the Board of ImmuneEdge (private) and IndoUSrare, a non-profit dedicated to accelerating therapies for rare diseases in global markets, including India. Dr. Bhatnagar obtained his medical degree at SMS Medical College in Jaipur, India and completed his residency and fellowship training in the U.S. at various institutions, including Georgetown University Hospital and the University of Pennsylvania.